Observational studyJournal of comparative effectiveness research2025

Real-world ePRO use and clinical outcomes using electronic patient-reported symptom monitoring for patients with advanced non-small-cell lung cancer receiving first-line pembrolizumab.

L Johnetta Blakely et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.